Scarica l'app Stockscreener
14.55
3.00%
-0.45
Dopo l'orario di chiusura:
14.55
Precedente Chiudi:
$15.00
Aprire:
$14.82
Volume 24 ore:
1.34M
Relative Volume:
2.48
Capitalizzazione di mercato:
$442.74M
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-2.8035
EPS:
-5.19
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
-6.67%
1M Prestazione:
-28.36%
6M Prestazione:
-36.44%
1 anno Prestazione:
-25.42%
Intervallo 1D:
$14.20
$15.29
Intervallo di 1 settimana:
$14.20
$17.34
Portata 52W:
$14.20
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
14.55 | 442.74M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Franklin Resources Inc. Has $12.31 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Truist Financial Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co. - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Wellington Management Group LLP Grows Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio shares target cut, hold rating kept on trial failure By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's What Happened - MarketBeat
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings) - Benzinga
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout - Seeking Alpha
Truist Financial Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $20.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Here's What Happened - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Sees Significant Growth in Short Interest - Defense World
Short Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Grows By 5.8% - MarketBeat
Wedbush Has Negative Forecast for AnaptysBio FY2024 Earnings - MarketBeat
Analysts Set Expectations for AnaptysBio FY2024 Earnings - MarketBeat
AnaptysBio FY2024 EPS Estimate Increased by HC Wainwright - Defense World
Guggenheim Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $36.00 - Defense World
Q1 Earnings Forecast for AnaptysBio Issued By HC Wainwright - Defense World
Charles Schwab Investment Management Inc. Has $5.37 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio stock hits 52-week low at $14.2 amid market shifts - Investing.com Australia
AnaptysBio (NASDAQ:ANAB investor three-year losses grow to 55% as the stock sheds US$261m this past week - Simply Wall St
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated - MSN
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals - MSN
AnaptysBio shares target cut, maintains Buy rating on phase study results - Investing.com UK
HC Wainwright & Co. Downgrades AnaptysBio (ANAB) - MSN
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints - Yahoo Finance
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio stock hits 52-week low at $14.2 amid market shifts By Investing.com - Investing.com South Africa
AnaptysBio reports failed Phase 2B trial, maintains cash reserves By Investing.com - Investing.com Canada
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data - Yahoo Finance
Anaptys scraps development of ANB032, stock plunges 33% - MSN
AnaptysBio drops development of ANB032 following trial miss - The Pharma Letter
Anaptys Announces Phase 2B Trial of ANB032, A Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - Marketscreener.com
AnaptysBio to abandon eczema drug development after mid-stage trial failure - Reuters.com
Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall - MarketWatch
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - The Manila Times
Anaptysbio (ANAB) Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - StreetInsider.com
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in - EIN News
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Frazier Life Sciences Management L.P. - MarketBeat
Point72 Asset Management L.P. Buys 36,300 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Verition Fund Management LLC Acquires Shares of 22,036 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
JP Morgan Upgrades AnaptysBio (ANAB) - MSN
BNP Paribas Financial Markets Purchases 65,027 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Intech Investment Management LLC Invests $229,000 in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Fmr LLC Purchases 438,557 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Parkman Healthcare Partners LLC Reduces Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
BTIG Downgrades AnaptysBio (ANAB) - MSN
AnaptysBio (NASDAQ:ANAB) Lowered to “Neutral” Rating by BTIG Research - Defense World
BTIG cuts AnaptysBio shares to neutral on high-risk trial setup - Investing.com Canada
Key Takeaways From AnaptysBio Analyst Ratings - Inkl
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anaptysbio Inc Azioni (ANAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Sale |
25.00 |
10,000 |
250,000 |
1,950 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):